generic and biosimilar medicines Archives | Be Korea-savvy
Sandoz Reports Year-to-date Sales for the First Nine Months of 2023

Sandoz Reports Year-to-date Sales for the First Nine Months of 2023

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz® launch, approval of Tyruko® in US and Europe, partnership on ustekinumab and closing of Mycamine® acquisition Full-year 2023 guidance confirmed [...]